Nesvold A, Ly B, Abildgaard U, Stiris M
Medisinsk avdeling, Aker sykehus, Oslo.
Tidsskr Nor Laegeforen. 1991 Nov 10;111(27):3296-7.
At our department, the routine treatment of deep venous thrombosis is low molecular weight heparin (Fragmin) in doses of 80-120 anti-Xa Units/Kg body weight/12h subcutaneously. In an open study we found that anti-thrombotic efficacy of the treatment, and safety with regard to bleeding, was the same as found in controlled studies. The patient population was characterized by old age and high morbidity. Nevertheless, eight out of 30 patients (26%) could be transferred to ambulant care on day 2-4. We conclude that low molecular weight heparin facilitates out-patient care of uncomplicated cases of deep venous thrombosis.
在我们科室，深部静脉血栓形成的常规治疗是皮下注射低分子量肝素（速碧林），剂量为80 - 120抗Xa单位/千克体重/12小时。在一项开放性研究中，我们发现该治疗的抗血栓疗效以及出血安全性与对照研究中的结果相同。患者群体以老年和高发病率为特征。然而，30名患者中有8名（26%）在第2 - 4天能够转为门诊治疗。我们得出结论，低分子量肝素有助于非复杂性深部静脉血栓形成病例的门诊治疗。
